Genmab A/S re-affirmed revenue guidance for the year 2024. For the year 2024, the company?s revenue guidance is unchanged and expected to be in the range of DKK 18.7 billion to DKK 20.5 billion.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2,034 DKK | -1.50% | +2.31% | -5.52% |
May. 15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
May. 15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.52% | 19.43B | |
+7.30% | 113B | |
+11.01% | 106B | |
+0.87% | 22.27B | |
-12.31% | 22.22B | |
-37.85% | 17.87B | |
-5.99% | 17.24B | |
+7.05% | 14.29B | |
+34.83% | 12.52B | |
+303.92% | 8.6B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Re-Affirms Revenue Guidance for the Year 2024